Table 3.
COPD therapy for stable COPD in the prevalent and incident cohorts
| Prevalent cohort (N=49,286), n (%) |
Incident cohort (N=27,224), n (%) |
|
|---|---|---|
| Total monotherapies | 12,710 (25.8) | 13,215 (48.5) |
| SABA | 5,499 (11.2) | 7,645 (28.1) |
| SAMA | 272 (0.6) | 403 (1.5) |
| LABA | 1,209 (2.5) | 1,323 (4.9) |
| LAMA | 4,977 (10.1) | 3,299 (12.1) |
| LAMA + SABA | 3,466 (69.6) | 2,462 (74.6) |
| LAMA + SAMA | 96 (1.9) | 90 (2.7) |
| Methylxanthines | 26 (0.1) | 2 (0.01) |
| ICS | 637 (1.3) | 493 (1.8) |
| OCS | 90 (0.2) | 50 (0.2) |
| Total combination therapies | 27,561 (55.9) | 7,167 (26.3) |
| LABA + ICS (as both FDC and combination) | 9,896 (20.1) | 3,686 (13.5) |
| LABA + ICS + SABA | 7,505 (75.8) | 2,980 (80.9) |
| LABA + ICS + SAMA | 1,219 (12.3) | 247 (6.7) |
| LABA + LAMA + ICS | 14,088 (28.6) | 2,044 (7.5) |
| LABA + LAMA + ICS + SABA | 12,137 (86.2) | 1,716 (84.0) |
| LABA + LAMA + ICS + SAMA | 382 (2.7) | 104 (5.1) |
| LAMA + ICS | 210 (0.4) | 106 (0.4) |
| LAMA + ICS + SABA | 155 (73.8) | 81 (76.4) |
| LAMA + ICS + SAMA | 5 (2.4) | 7 (6.6) |
| LABA + LAMA | 844 (1.7) | 480 (1.8) |
| SABA + SAMA only | 472 (1.0) | 647 (2.4) |
| Methylxanthines + ICS | 440 (0.9) | 55 (0.2) |
| Methylxanthines + LABA | 20 (0.0) | 24 (0.1) |
| Methylxanthines + LAMA | 67 (0.1) | 16 (0.1) |
| Methylxanthines + (LABA or LAMA or ICS) | 1,524 (3.1) | 109 (0.4) |
| Any other combinations | 28 (0.1) | 7 (0.03) |
| Patients not on any of the above treatments | 8,987 (18.2) | 6,835 (25.1) |
Abbreviations: ICS, inhaled corticosteroids; FDC, fixed-dose combination; LABA, long-acting beta agonists; LAMA, long-acting anticholinergics; n, number of patients; OCS, oral corticosteroids; SABA, short-acting beta agonists; SAMA, short-acting anticholinergics.